Copernicus raises $1m for cystic fibrosis work

Jan. 24, 2005 — Copernicus Therapeutics Inc. announced it received an extension to its therapeutics development award from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), according to a company release.

The $750,000 award was coupled with a $280,000 outstanding payment from the original therapeutics development award to bring the total payment to $1.03 million.

The award extension is intended to support the Phase II advancement of Copernicus’ potential genetic therapy for cystic fibrosis. Copernicus’ non-viral nanoparticle formulation is intended to deliver a normal copy of the cystic fibrosis gene to the affected airway cells of people with the disease.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.